

U.S.S.N. 10/012,202
Filed: December 5, 2001
AMENDMENT UNDER 37 C.F.R. 1.312

In the Claims

1. (previously presented) A biphasic antihistamine composition in daily oral uni-dosage or divided dosage form which comprises:
 - (a) a therapeutically effective amount of a sedating antihistamine to inhibit histamine release for a duration of about 4 to 12 hours, and
 - (b) a therapeutically effective amount of non-sedating antihistamine to inhibit histamine release for a duration of 10 to 20 hours, with a delayed release 6 to 10 hours after ingestion,wherein the delayed release portion is achieved by coating a core or granulations with at least one delayed release control polymer.
2. (previously presented) The antihistamine composition defined in claim 1 wherein the sedating antihistamine is selected from the group consisting of brompheniramine, chlorpheniramine, debrompheniramine, dexchlorpheniramine, carbinoxamine, clemastine, diphenhydramine, pyrilamine, tripeleannamine, tripolidine, methdilazine, bromodiphenhydramine, promethazine, azatadine, cyproheptadine, diphenylpyraline, doxylamine, trimeprazine, phenindamine, ketotifen, hydroxyzine, tazifylline, temelastine, meclizine, acrivastine, setastine, oxatomide, mequitazine, levocabastine, lodoxamide, AHR 11325, phenindamine, azelastine, and ebastine, or a pharmaceutically acceptable salt thereof.
3. (previously presented) The antihistamine composition defined in claim 1 wherein the non-sedating antihistamine is selected from the group consisting of fexofenadine, loratadine,

U.S.S.N. 10/012,202

Filed: December 5, 2001

AMENDMENT UNDER 37 C.F.R. 1.312

descarboethoxy loratadine, astemizole, norastemizole, desmethylastemizole, cetirizine, acrivastine, and temelastine, or a pharmaceutically acceptable salt thereof.

4. (previously presented) The antihistamine composition defined in claim 1 wherein the sedating antihistamine has a duration of activity of about 6 to 10 hours.

5. (previously presented) The antihistamine composition defined in claim 1 wherein the non-sedating antihistamine has a duration of activity of about 12 to 18 hours.

6. (previously presented) The antihistamine composition defined in claim 1 wherein the sedating antihistamine is releasable immediately or up to 1 hour following administration.

7. (previously presented) The antihistamine composition defined in claim 1 wherein the non-sedating antihistamine is releasable immediately or up to 1 hour following administration.

8. (previously presented) The antihistamine composition defined in claim 1 which further comprises a therapeutically effective amount of at least one agent selected from the group consisting of an analgesic agent, an antitussive agent, an expectorant, an anti-inflammatory agent, an anti-pyretic agent and a decongestant.

9. (previously presented) A method of inhibiting the release of histamine in a patient which comprises the step of administering to the patient, a therapeutically effective amount of the antihistamine composition defined in claim 1.

U.S.S.N. 10/012,202

Filed: December 5, 2001

AMENDMENT UNDER 37 C.F.R. 1.312

10. (previously presented) The method of inhibiting the release of histamine defined in claim 9 wherein the antihistamine composition is administered during the evening or night and the sedating antihistamine is immediately released.

11. (previously presented) The method of inhibiting the release of histamine defined in claim 9 wherein the antihistamine composition is administered during the evening or night and the non-sedating antihistamine is released the next day, 6 to 10 hours following administration.

12. (previously presented) The method of inhibiting the release of histamine defined in claim 9 wherein the patient suffers from allergic reaction, allergic rhinitis, cold or flu.

13. (previously presented) A biphasic antihistamine composition in daily oral uni-dosage or divided dosage form which comprises:

- (a) a therapeutically effective amount of a non-sedating antihistamine to inhibit histamine release for a duration of about 10 to 20 hours, and
- (b) a therapeutically effective amount of sedating antihistamine to inhibit histamine release for a duration of 4 to 12 hours, with a delayed release, 8 to 12 hours after ingestion.

14. (previously presented) The antihistamine composition defined in claim 13 wherein the non-sedating antihistamine is selected from the group consisting of fexofenadine, loratadine, descarboethoxy loratadine, astemizole, norastemizole, desmethylastemizole, cetirizine, acrivastine, and temelastine, or a pharmaceutically acceptable salt thereof.

15. (previously presented) The antihistamine composition defined in claim 13 wherein the sedating antihistamine is selected from the group consisting of brompheniramine,

U.S.S.N. 10/012,202

Filed: December 5, 2001

AMENDMENT UNDER 37 C.F.R. 1.312

chlorpheniramine, debrompheniramine, dexchlorpheniramine, carbinoxamine, clemastine, diphenhydramine, pyrilamine, tripeleennamine, tripolidine, methdilazine, bromodiphenhydramine, promethazine, azatadine, cyproheptadine, diphenylpyraline, doxylamine, trimeprazine, phenindamine, ketotifen, hydroxyzine, tazifylline, temelastine, meclizine, acrivastine, setastine, oxatomide, mequitazine, levocabastine, lodoxamide, AHR 11325, phenindamine, azelastine, and ebastine, or a pharmaceutically acceptable salt thereof.

16. (previously presented) The antihistamine composition defined in claim 13 wherein the non-sedating antihistamine has a duration of activity of about 12 to 18 hours.

17. (previously presented) The antihistamine composition defined in claim 13 wherein the sedating antihistamine has a duration of activity of about 6 to 10 hours.

18. (previously presented) The antihistamine composition defined in claim 13 wherein the non-sedating antihistamine is releasable immediately or up to 1 hour following administration.

19. (previously presented) The antihistamine composition defined in claim 13 which further comprises at least one agent selected from the group consisting of an analgesic agent, an antitussive agent, an expectorant, an anti-inflammatory agent, an anti-pyretic agent and a decongestant.

20. (previously presented) A method of inhibiting the release of histamine in a patient which comprises the step of administering to the patient, a therapeutically effective amount of the antihistamine composition defined in claim 13.

U.S.S.N. 10/012,202

Filed: December 5, 2001

AMENDMENT UNDER 37 C.F.R. 1.312

21. (previously presented) The method of inhibiting the release of histamine defined in claim 20 wherein the antihistamine composition is administered during the day and the non-sedating antihistamine is immediately released.

22. (previously presented) The method of inhibiting the release of histamine defined in claim 20 wherein the antihistamine composition is administered during the day and the sedating antihistamine is released in the evening or night, 8 to 12 hours following administration.

23. (previously presented) The method of inhibiting the release of histamine defined in claim 20 wherein the patient suffers from allergic reaction, allergic rhinitis, cold or flu.

24. (previously presented) The antihistamine composition defined in claim 1 wherein the delayed release portion is achieved by coating a core or granulations with at least one delayed release control polymer selected from the group consisting of ethyl cellulose, cellulose acetate, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, acrylic acid polymers and copolymers, polymers or copolymers of methacrylic acid, methyl acrylate, ethyl acrylate, methyl methacrylate, ethyl methacrylate, hydroxypropyl methylcellulose acetate succinate, shellac, cellulose acetate trimellitate, vinyl acetate, azo polymers, pectin, chitosan, amylose, guar gum, and zein or combination thereof.

25. (previously presented) The antihistamine composition defined in claim 8 wherein the analgesic agent, antitussive agent, expectorant, anti-inflammatory agent or decongestant is in a sustained release form.

U.S.S.N. 10/012,202
Filed: December 5, 2001
AMENDMENT UNDER 37 C.F.R. 1.312

26. (currently amended) The antihistamine composition defined in claim 25 wherein the sustained release effect is achieved by formulating the analgesic agent, antitussive agent, expectorant, anti-inflammatory agent or decongestant with a sustained-release control polymer selected from the group consisting of methyl cellulose, ethyl cellulose, wax, gums, cellulose acetate, cellulose acetate phthalate, hydroxypropylmethylcellulose ~~succinate~~ phthalate, polyvinyl acetate phthalate, acrylic acid polymers and copolymers, polymers or copolymers of methacrylic acid, methyl acrylate, ethyl acrylate, methyl methacrylate, ethyl methacrylate, hydroxypropyl methylcellulose acetate succinate, shellac, cellulose acetate trimellitate, vinyl acetate and combination thereof.

27. (previously presented) The antihistamine composition defined in claim 13 wherein the delayed release portion is achieved by coating a core or granulations with at least one delayed release control polymer selected from the group consisting of ethyl cellulose, cellulose acetate, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, acrylic acid polymers and copolymers, polymers or copolymers of methacrylic acid, methyl acrylate, ethyl acrylate, methyl methacrylate, ethyl methacrylate, hydroxypropyl methylcellulose acetate succinate, shellac, cellulose acetate trimellitate, vinyl acetate, azo polymers, pectin, chitosan, amylose, guar gum, and zein or combination thereof.

28. (previously presented) The antihistamine composition defined in claim 19 wherein the analgesic agent, antitussive agent, expectorant, anti-inflammatory agent or decongestant is in an immediate release form or in a sustained release form.

U.S.S.N. 10/012,202

Filed: December 5, 2001

AMENDMENT UNDER 37 C.F.R. 1.312

29. (currently amended) The antihistamine composition defined in claim 28 wherein the sustained release effect is achieved by formulating the analgesic agent, antitussive agent, expectorant, anti-inflammatory agent or decongestant with a sustained-release control polymer selected from the group consisting of methyl cellulose, ethyl cellulose, wax, gums, cellulose acetate, cellulose acetate phthalate, hydroxypropylmethylcellulose ~~succinate~~ phthalate, polyvinyl acetate phthalate, acrylic acid polymers and copolymers, polymers or copolymers of methacrylic acid, methyl acrylate, ethyl acrylate, methyl methacrylate, ethyl methacrylate, hydroxypropyl methylcellulose acetate succinate, shellac, cellulose acetate trimellitate, vinyl acetate and combination thereof.